KRAS and neoplasm: Addition of epidermal growth factor receptor (EGFR)-targeted agents (e.g. the chimeric antibody cetuximab or the fully human antibody panitumumab) to FOLFIRI also significantly improves outcomes in patients with wild-type (WT) KRAS tumours[3,4].